重组人肝细胞生长因子裸质粒(Viromed)(Donaperminogene seltoplasmid(Viromed)) - 药物靶点：HGF_在研适应症：下肢缺血，溃疡，慢性肢体威胁性缺血_专利_临床

概要

基本信息

药物类型

基因疗法

别名

Hepatocyte growth factor gene therapy(Helixmith)、HGF plasmid、Modified hepatocyte growth factor gene therapy(Helixmith)

+ [12]

靶点

HGF

作用方式

刺激剂、诱导剂

作用机制

HGF刺激剂(肝细胞生长因子刺激剂)、血管生成诱导剂

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

下肢缺血溃疡慢性肢体威胁性缺血+ [10]

非在研适应症

急性心肌梗塞稳定型心绞痛腓骨肌萎缩症Ia型+ [2]

原研机构

在研机构

+ [2]

非在研机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)申请上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 319545129

来源: *****

关联

25

项与重组人肝细胞生长因子裸质粒(Viromed) 相关的临床试验

NCT05968118

/ Recruiting临床3期

A Double-Blind, Randomized, Placebo-Controlled, Single Center Study to Assess the Angiogenesis and Blood Perfusion Effect of NL003 in Patients With Critical Limb Ischemia by PETCT-RGD and MIBI

The purpose of this study is to evaluate whether PET/CT-RGD or MIBI can be used for the angiogenesis assessment of NL003 in PAD patients.

开始日期2022-07-29

申办/合作机构

北京诺思兰德生物技术股份有限公司

CTR20221646

/ Completed临床3期

联合 68Ga-RGD PET 和 99mTc-MIBI SPECT 影像学方法评估 NL003 在治疗慢性下肢缺血过程中对血管新生及下肢血流灌注量的影响，评价药物的有效性和安全性。

开始日期2022-07-29

申办/合作机构

北京诺思兰德生物技术股份有限公司

NCT05176093

/ Completed临床2期

A 6-Month Extension Study Following Protocol VMALS-002-2 (A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis)

The purpose of this study is to evaluate the long-term safety of intramuscular (IM) administration of Engensis in Participants with Amyotrophic Lateral Sclerosis (ALS) who were previously randomized, received treatment, and completed the Day 180 Visit of Study VMALS-002-2. Safety will be assessed by incidences of treatment-emergent adverse events (TEAEs), treatment emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and the clinically significant laboratory values. See the table below for additional, exploratory endpoints.

开始日期2021-11-14

申办/合作机构

Helixmith Co., Ltd.

100 项与重组人肝细胞生长因子裸质粒(Viromed) 相关的临床结果

登录后查看更多信息

100 项与重组人肝细胞生长因子裸质粒(Viromed) 相关的转化医学

登录后查看更多信息

100 项与重组人肝细胞生长因子裸质粒(Viromed) 相关的专利（医药）

登录后查看更多信息

27

项与重组人肝细胞生长因子裸质粒(Viromed) 相关的文献（医药）

2025-08-01·TISSUE & CELL

Optimal injection sites for therapeutic angiogenesis: HGF-mediated regulation of HIF-1α via MAPK/PI3K pathways in hypoxic endothelial cells

Article

作者: Wang, Wenjing ; Ni, Leng ; Sun, Guoqiang ; Liu, ChangWei ; Zhong, Qing ; Rong, Zhihua ; Di, Xiao ; Chen, Tianqi ; Qiu, Hongjuan ; Ma, ShanShan ; Lian, Wenzhuo ; Li, Zongshu ; Li, Fengshi ; Wang, Peng

Therapeutic angiogenesis offers a promising strategy for patients with critical limb-threatening ischemia (CLTI) who are unsuitable candidates for revascularization. However, the optimal administration sites for gene therapy agents, such as pCK-HGF-X7, remains undefined. Clinical trials commonly employ multiple intramuscular injections at sites of arterial occlusion; yet the necessity and efficacy of such extensive and repetitive protocols remains unclear. Targeted injections into ischemic tissues or their margins may improve therapeutic outcomes. Moreover, the molecular mechanisms by which hepatocyte growth factor (HGF)/c-Met signaling regulates hypoxia-inducible factor-1α (HIF-1α) expression under hypoxic conditions are not fully understood. This study aims to elucidate these molecular mechanisms in endothelial cells under hypoxic conditions and to identify the most effective injection sites for therapeutic angiogenesis agents. The effects of various HGF isoforms/complexes on human aortic endothelial cells (HAECs) were evaluated under normoxic and hypoxic conditions, focusing on proliferation, migration, and tube formation. Pathway inhibitors were used to explore the underlying mechanisms in hypoxic HAECs, and the findings were validated in a rat hindlimb ischemia model. Results demonstrated that HGF₇₂₃ and HGF₇₂₈ activated the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, regulating HIF expression and significantly enhanced endothelial cell proliferation, migration, and tube formation, particularly under hypoxia. Despite these cellular effects, HGF treatment did not significantly improve tissue perfusion or neovascularization in normal rat hindlimbs. However, in ischemic rat hindlimbs, it markedly promoted angiogenesis and improved tissue perfusion in the gastrocnemius muscle. These findings indicate that therapeutic angiogenesis agents should primarily target hypoxic tissues, extending to the interface between normoxic and hypoxic regions, to optimize treatment efficacy.

2025-01-01·JOURNAL OF VASCULAR SURGERY

Hepatocyte growth factor for walking performance in peripheral artery disease

Article

作者: Sufit, Robert ; Parekh, Nishant D ; Kramer, Christopher M ; Ferrucci, Luigi ; Tian, Lu ; Peterson, Charlotte A ; Domanchuk, Kathryn J ; Zhao, Lihui ; Volpe, Nicholas J ; Ismaeel, Ahmed ; Polonsky, Tamar ; Zhang, Dongxue ; Ho, Karen ; McDermott, Mary M ; Xu, Shujun ; Kosmac, Kate ; Lloyd-Jones, Donald ; Guralnik, Jack M ; Kibbe, Melina R ; Leeuwenburgh, Christiaan ; Criqui, Michael H

BACKGROUND:

VM202 is a plasmid encoding two isoforms of hepatocyte growth factor. In preclinical studies, hepatocyte growth factor stimulated angiogenesis and muscle regeneration. This preliminary clinical trial tested the hypothesis that VM202 injections in gastrocnemius muscle would improve walking performance in people with mild to moderate and symptomatic lower extremity peripheral artery disease (PAD).

METHODS:

In a double-blind clinical trial, patients with PAD were randomized to gastrocnemius muscle injections of either 4 mg of VM202 or placebo every 14 days for four treatments. The primary outcome was 6-month change in 6-minute walk distance. Secondary outcomes included 3-month change in treadmill walking time and gastrocnemius muscle biopsy measures. In this preliminary trial, statistical significance was prespecified as a one-sided P value of less than .10.

RESULTS:

Thirty-nine participants with PAD (64.1% Black, 28.2% female) were randomized. Adjusting for age, race, smoking, and baseline performance, VM202 did not improve 6-minute walk at 6-month follow-up, compared with placebo (-13.5 m; 90% confidence interval [CI], -38.5 to +∞). At the 3-month follow-up, VM202 improved the maximum treadmill walking time (+2.38 minutes; 90% CI, +1.08 to +∞; P = .014) and increased central nuclei abundance in gastrocnemius muscle (+5.86; 90% CI, +0.37 to +∞; P = .088), compared with placebo. VM202 did not significantly improve pain-free walking distance (difference, +0.30 minutes; 90% CI, -1.10 to +∞; P = .39), calf muscle perfusion (difference, +1.80 mL/min per 100 g tissue; 90% CI, -3.80 to +∞; P = .33), or the Walking Impairment Questionnaire distance score (difference, +2.02; 90% CI, -8.11 to +∞; P = .40). In post hoc analyses, VM202 significantly improved 6-minute walk in PAD participants with diabetes mellitus at 6-month follow-up (+34.19; 90% CI, 4.04 to +∞; P = .075), but had no effect in people without diabetes (interaction P = .079).

CONCLUSIONS:

These data do not support gastrocnemius injections of VM202 to improve 6-minute walk in PAD. Secondary outcomes suggested potential benefit of VM202 on skeletal muscle measures and treadmill walking, whereas post hoc analyses suggested benefit in PAD participants with diabetes.

2023-11-01·International wound journal

Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo‐controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor

Article

作者: Loveland, Lacey ; Dove, Cyaandi ; Armstrong, David G ; Motley, Travis ; Sigal, Felix ; Caporusso, Joseph ; Vartivarian, Mher ; Perin, Emerson ; Oliva, Francisco

Abstract:

To evaluate the status of a 7‐month phase 3 study conducted to test the effect of intramuscular injections of VM202 (ENGENSIS), a plasmid DNA encoding human hepatocyte growth factor, into the calf muscles of chronic nonhealing diabetic foot ulcers with concomitant peripheral artery disease. The phase 3 study, originally aimed to recruit 300 subjects, was discontinued because of slow patient recruitment. An unprespecified interim analysis was performed for the 44 subjects enrolled to assess the status and determine the future direction. Statistical analyses were carried out for the Intent‐to‐Treat (ITT) population and separately for subjects with neuroischemic ulcers, using a t‐test and Fisher's exact test. A logistic regression analysis was also conducted. VM202 was safe and potentially should have benefits. In the ITT population (N = 44), there was a positive trend toward closure in the VM202 group from 3 to 6 months but with no statistical significance. Levels of ulcer volume or area were found to be highly skewed between the placebo and VM202 groups. Forty subjects, excluding four outliers in both arms, showed significant wound‐closing effects at month 6 (P = .0457). In 23 patients with neuroischemic ulcers, the percentage of subjects reaching complete ulcer closure was significantly higher in the VM202 group at months 3, 4, and 5 (P = .0391, .0391, and .0361). When two outliers were excluded, a significant difference was evident in months 3, 4, 5, and 6 (P = .03 for all points). A potentially clinically meaningful 0.15 increase in Ankle‐Brachial Index was observed in the VM202 group at day 210 in the ITT population (P = .0776). Intramuscular injections of VM202 plasmid DNA to calf muscle may have promise in the treatment of chronic neuroischemic diabetic foot ulcers (DFUs). Given the safety profile and potential healing effects, continuing a larger DFU study is warranted with modifications of the current protocol and expansion of enrolling sites.

35

项与重组人肝细胞生长因子裸质粒(Viromed) 相关的新闻（医药）

2025-04-16

·northland-bio.com

通州区政协主席张德启率医药卫生界别委员调研诺思兰德

4月15日，北京市通州区政协主席张德启带领医药卫生界别委员一行10人莅临公司通州产业化基地考察调研，深入了解诺思兰德新药研发、产业基地建设及药品商业化筹备等情况。通州区政协秘书长陈立军、通州区政协委员、卫生健康委主任陈长春等领导陪同调研。公司董事长许松山、常务副总裁聂李亚、副总裁韩成权及子公司生物制药副总经理王永江等领导热情接待了调研组一行。座谈会上，子公司副总经理王永江详细汇报了公司发展历程、创新药物研发进展及产业化布局。重点介绍了公司核心产品塞多明基注射液（NL003）的审评进展以及商业化准备情况。公司常务副总裁兼汇恩兰德总经理聂李亚向调研组汇报了眼科药品的研发、生产和公司经营情况。目前，汇恩兰德已建立起覆盖常见眼科疾病的药品体系，并正在布局高端眼科药品领域。公司董事长许松山向调研组介绍了建设中的生物工程产业化基地。该基地按照自动化、数字化、智能化的高标准建设，力争打造生物工程药厂的样本。目前正在以EPC总包模式，联合楚天科技进行生产车间的设计、设备采购及安装，年内将完成设备的安装、调试及验证，具备生产能力。该产线规划年产能120万支，不仅能满足NL003的商业化生产需求，还具备重组蛋白质类、抗体类药物的生产能力，并为未来产能扩展预留了充足空间，建成后有望成为我国首个专业人用裸质粒基因治疗药物生产基地。在公司领导的陪同下，调研组成员实地参观了眼科药生产车间，深入了解眼科制剂的生产工艺和质量控制体系，并参观了新建04线全自动BFS滴眼液生产线。该产线年生产能力为1.5亿支，并已通过GMP现场符合性检查，即将投入使用。届时，汇恩兰德滴眼液年生产能力将达到2.6亿支，大幅提升公司的创收能力。调研组一行对诺思兰德团队坚持科技创新20年的坚韧及取得的成绩表示钦佩。张德启主席表示：诺思兰德研发的全球首个裸质粒基因治疗药物获批在即，不仅展现了企业的创新实力，更是通州区生物医药产业高质量发展的生动体现。他强调，通州区将落实国务院《全链条支持创新药发展实施方案》及《北京市支持医药高质量发展若干措施》的精神，持续优化营商环境，加快医产协同创新成果转化，畅通创新药进院及用药路径，并在人才引进、审批服务、产业配套等方面给予重点支持，助力诺思兰德加快实现创新成果转化。公司董事长许松山表示：诺思兰德始终坚持以创新驱动发展，在生物医药领域积累了丰富的研发经验和核心技术。他对多年来一直给予诺思兰德关心支持的各级政府机构表示感谢，感谢通州区政协领导率队调研。公司将全力推进商业化布局，以NL003上市为契机，实现从单一科技研发向集研发、生产、商业化为一体的制药企业转型，为我国生物医药产业高质量发展做出更大贡献。

带量采购高管变更基因疗法

2025-04-15

·northland-bio.com

塞多明基注射液获美国专利授权，夯实核心技术优势与知识产权保护体系

近日，诺思兰德在研重点创新药项目“塞多明基注射液”（项目代号NL003）的专利PCT国际专利申请获得美国发明专利授权, 专利名称为“HUMAN HEPATOCYTE GROWTH FACTOR MUTANT AND USES THEREOF”（人肝细胞生长因子突变体及其应用）（专利号：US012264186B2）”。截止目前，公司创新药NL003项目已构建了覆盖质粒结构、工艺等核心技术的知识产权保护体系，形成了全面、系统的专利布局。塞多明基注射液是诺思兰德自主研发的首款基因治疗药物，适应症为慢性下肢缺血性疾病（CLI），已于2024年7月申报NDA，并已完成全部技术审评工作。NL003作为全新的裸质粒基因治疗药物，具有三大全球首创先进性：其一，NL003为全球首个治疗下肢缺血性疾病的基因治疗药物，可为CLI患者提供传统药物和手术之外的全新治疗选择；其二，NL003为全球首个促血管新生的治疗性药物。通过促进新生血管再生，建立“分子搭桥”机制，从而实现从“对症治疗”向“对因治疗”的转变；其三，NL003为全球首个裸质粒载体的基因治疗药物。NL003以裸质粒为载体，局部注射后质粒转染横纹肌细胞，持续表达和分泌具有促进血管生长作用的HGF蛋白，显著提升治疗效果和患者依从性。与传统的药物和手术治疗方案比较，塞多明基注射液属于再生医学先进疗法(RMAT),为临床治疗下肢动脉缺血疾病提供第三种更安全有效的治疗方案，更好的减轻病人痛苦与提供生活质量，减少家庭及社会负担，可产生明显的经济效益和社会效益。目前，世界范围内针对CLI尚无有效的治疗药物，临床治疗主要依靠介入及血管搭桥等外科手术方式，治疗手段有限，治疗效果不理想。NL003是一种创新型基因治疗药物，以裸质粒为载体，通过在缺血部位的局部肌肉注射NL003，质粒转染横纹肌细胞并持续表达和分泌具有促进血管生长作用的肝细胞生长因子HGF蛋白，促进新生血管再生，在缺血部位形成侧支循环，建立“分子搭桥”机制，增加缺血部位的血流供应，从而达到疾病治疗作用。与传统的血管重建手术方式比，NL003在创伤性、操作便捷性、疗效和持久性上具有明显优势，可为患者带来持续的临床获益。据中华心血管健康与疾病报告2022报道，在我国35岁以上的自然人群中下肢PAD（外周动脉疾病）的患病率为6.6%，约有4530万例，约10%的下肢PAD患者会进展为CLI，且CLI发病率高、病程长、致残率高，5年死亡率超过50%，远高于大部分癌症等危重疾病。随着我国社会经济的发展和医疗条件的改善，人均寿命延长，老年人口数量不断增加，老龄化进程加快，未来CLI患病人数预计持续增加，存在显著的未满足医疗需求。公司高度重视在研新药的知识产权全方位保护，NL003作为公司原创的物理靶向新药，根据项目创新性及特点制定了完善的专利和商标保护策略。专利保护方面，本次新增美国发明专利授权为相关药品及产品用途专利，形成裸质粒基因治疗药物平台的新药开发技术一系列核心技术的知识产权保护，构建了高效的专利保护网，形成了有利于项目保护的专利组合。未来将根据专利保护策略，持续优化全球专利布局，延长产品全生命周期的知识产权保护。商标品牌建设方面，以“华索灵”为商品名，注重品牌建设与保护，提升产品市场辨识度。本次塞多明基注射液项目获得美国专利授权，标志着诺思兰德在裸质粒基因治疗药物领域的技术领先优势进一步巩固。公司将继续以知识产权为核心驱动力，持续创新，为患者提供更优质的治疗选择，同时为企业的长期发展奠定坚实基础。

基因疗法抗体药物偶联物临床研究突破性疗法

2025-04-14

·northland-bio.com

诺思兰德与韩国EpiBiotech签订战略合作协议

【概要描述】2025年4月11日，韩国EpiBiotech公司社长Sung Jong-Hyuk博士一行3人来访我司，公司董事长许松山、副总裁韩成权、研发总监马杉姗等进行了接待。双方相互介绍了公司基本情况及在研产品管线，并深入交流了CGT领域最新技术动态。双方就细胞治疗领域技术合作达成意向并签署战略合作框架协议（MOU）。 2025年4月11日，韩国EpiBiotech公司社长Sung Jong-Hyuk博士一行3人来访我司，公司董事长许松山、副总裁韩成权、研发总监马杉姗等进行了接待。双方相互介绍了公司基本情况及在研产品管线，并深入交流了CGT领域最新技术动态。双方就细胞治疗领域技术合作达成意向并签署战略合作框架协议（MOU）。韩国Epibiotech公司是一家专注于脱发治疗产品研发的生物技术公司，拥有细胞疗法、抗体疗法、合成药物等多种脱发治疗手段。其主要细胞疗法在韩国已进入临床研究阶段。当前，细胞治疗产业正处于政策红利期与技术爆发期的叠加阶段。中国各级政府按照新质生产力的总体要求，加大对科技产业的支持力度，特别是对医药创新发展出台了全链条产业支持政策，审批加速、创新支付等政策支持更是推动CGT领域规模持续扩张。据弗若斯特沙利文数据，全球细胞基因治疗市场规模从2016年的5040万美元增至2020年的20.8亿美元，预计2025年将达305.4亿美元，2021-2025年复合年增长率为65.1%。中国市场增速更为显著，预计到2030年，中国细胞治疗市场规模将突破500亿元，成为全球第二大市场。公司董事长许松山表示，诺思兰德一直深耕基因治疗领域药物的研发，公司自主开发的塞多明基注射液（NL003）已进入新药上市审评的综合评审阶段，有望年内获批。通过该产品的研发，公司在基因治疗药物研发和产业化方面积累了从药学研究、临床前研究、临床研究、规模化生产、质量管理及注册申报全流程的经验。此次与EpiBiotech达成战略合作，符合公司发展战略和研发方向，有助于提升诺思兰德在CGT领域的核心技术，丰富公司产品管线。细胞治疗脱发项目市场前景广阔，据有关数据表明，目前我国脱发患者约有2.3亿，预测到2030年治疗市场达380亿元。双方将本着优势互补、公平、公正的原则，加速细胞治疗技术的研发和成果转化，并不断扩大合作范围，实现双赢。

细胞疗法基因疗法

100 项与重组人肝细胞生长因子裸质粒(Viromed) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
下肢缺血	申请上市	中国	北京诺思兰德生物技术股份有限公司	2024-07-15
下肢缺血	申请上市	中国	江苏耀海生物制药有限公司	2024-07-15
溃疡	申请上市	中国	北京诺思兰德生物技术股份有限公司	-
慢性肢体威胁性缺血	临床3期	美国	Helixmith Co., Ltd.	2017-06-27
糖尿病足溃疡	临床3期	美国	Helixmith Co., Ltd.	2017-06-27
糖尿病周围神经性疼痛	临床3期	美国	Helixmith Co., Ltd.	2016-04-01
糖尿病肾病	临床3期	中国	北京诺思兰德生物技术股份有限公司	-
糖尿病肾病	临床3期	-	Viromed, Inc.	-
外周动脉疾病	临床3期	-	Viromed, Inc.	-
静息痛	临床3期	中国	北京诺思兰德生物技术股份有限公司	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04275323 (NL003-CLI-III-1, NEWS) 人工标引	临床3期	下肢缺血	302	NL003	廠獵築鑰夢糧襯繭憲獵(簾淵淵鑰齋憲獵齋繭餘) = 膚齋餘願醖鹽廠構醖鹹窪憲廠願製廠淵積膚襯 (夢衊鹹蓋鏇鹽繭選蓋夢 ) 达到更多	积极	2025-02-23
				Placebo	廠獵築鑰夢糧襯繭憲獵(簾淵淵鑰齋憲獵齋繭餘) = 鏇淵製構觸襯願網網糧窪憲廠願製廠淵積膚襯 (夢衊鹹蓋鏇鹽繭選蓋夢 ) 达到更多
NCT04469270 (REGAiN-1A, CTgov)	临床3期	糖尿病周围神经性疼痛	162	Engensis (Engensis)	憲糧鑰鑰夢鏇觸鑰餘鏇(繭選積衊糧積遞願鑰窪) = 鏇製餘廠鬱糧艱觸顧選繭鏇蓋簾齋淵憲衊願繭 (觸齋鬱顧觸鹹憲網夢顧, 2.020) 更多	-	2025-01-20
				Placebo (Placebo)	憲糧鑰鑰夢鏇觸鑰餘鏇(繭選積衊糧積遞願鑰窪) = 廠選窪襯夢構顧壓淵積繭鏇蓋簾齋淵憲衊願繭 (觸齋鬱顧觸鹹憲網夢顧, 2.115) 更多
NCT04873232 (REGAiN-1B, CTgov)	临床3期	糖尿病周围神经性疼痛	106	Engensis (Engensis)	範糧蓋鬱鏇簾繭鏇壓壓(餘糧積繭鑰鏇鑰鑰淵廠) = 鏇鹹築製襯夢願膚淵鏇糧觸鏇獵製憲願顧築遞 (遞窪鏇醖餘顧範膚壓廠, 2.083) 更多	-	2025-01-16
				Placebo (Placebo)	範糧蓋鬱鏇簾繭鏇壓壓(餘糧積繭鑰鏇鑰鑰淵廠) = 齋蓋積鹹壓願觸廠繭鹽糧觸鏇獵製憲願顧築遞 (遞窪鏇醖餘顧範膚壓廠, 2.087) 更多
NCT00696124 (CTgov)	临床1期	慢性肢体威胁性缺血 \| 下肢缺血	12	VM202 2 mg (Cohort 1)	鏇網選鬱積窪衊夢簾網 = 衊選齋憲簾鹽鹹獵範艱積鑰夢蓋廠構艱獵鏇積 (願蓋鏇夢憲衊鑰衊淵獵, 齋製襯鹹願鏇願選繭獵 ~ 廠鹽願鬱選繭顧繭齋顧) 更多	-	2024-10-18
				VM202 4 mg (Cohort 2)	鏇網選鬱積窪衊夢簾網 = 鹽齋構襯廠鑰憲網鑰製積鑰夢蓋廠構艱獵鏇積 (願蓋鏇夢憲衊鑰衊淵獵, 衊夢窪鑰蓋壓鏇願積構 ~ 獵選餘觸製繭鹹鬱遞簾) 更多
NCT01064440 (CTgov)	临床2期	慢性肢体威胁性缺血	52	Placebo	獵醖醖鏇顧壓鏇齋夢夢 = 齋夢齋壓繭顧顧衊鑰齋鹹獵願窪憲觸鏇獵築鏇 (餘獵醖選襯窪遞艱獵壓, 製網窪蓋顧鏇簾壓壓顧 ~ 觸鬱繭衊窪壓齋糧淵淵) 更多	-	2024-09-19
NCT03363165 (HI-PAD, CTgov)	临床2期	外周动脉疾病	39	Placebo (Placebo)	夢鬱網簾淵艱壓餘鹽觸(艱餘鏇窪網憲夢鬱獵範) = 繭蓋艱壓簾築鬱膚夢範鹹襯簾膚築選蓋築願築 (鬱範鹽襯膚簾膚願顧繭, 13.76) 更多	-	2024-05-30
				VM202 (VM202)	夢鬱網簾淵艱壓餘鹽觸(艱餘鏇窪網憲夢鬱獵範) = 餘夢窪鑰艱簾簾繭鹹顧鹹襯簾膚築選蓋築願築 (鬱範鹽襯膚簾膚願顧繭, 12.70) 更多
NCT04274049 (NL003-CLI-III-2, Corporate Publications) 人工标引	临床3期	下肢缺血	242	NL003	襯網鏇構艱廠糧獵壓齋(製憲築糧憲顧網憲醖簾): P-Value = <0.0001 达到	积极	2024-02-02
				Normal Saline
NCT01475786 (CTgov)	临床2期	糖尿病周围神经性疼痛	104	VM202 (High Dose 32mg Engensis (VM202))	選觸餘鑰鑰衊襯鹽鹹夢(網鑰範廠膚壓願膚壓衊) = 壓簾鏇顧蓋鹽憲簾鏇簾膚製獵鹹觸衊窪鹽願襯 (網選窪簾蓋淵糧蓋衊膚, 1.96) 更多	-	2023-07-03
				Control- Placebo (normal saline)+Engensis (Low Dose 16mg Engensis (VM202) and Placebo)	選觸餘鑰鑰衊襯鹽鹹夢(網鑰範廠膚壓願膚壓衊) = 衊顧襯製蓋築遞膚窪淵膚製獵鹹觸衊窪鹽願襯 (網選窪簾蓋淵糧蓋衊膚, 2.23) 更多
NCT04055090 (CTgov)	临床3期	糖尿病周围神经性疼痛	101	Engensis (Subjects Who Received Engensis (VM202))	範膚夢壓艱構鹹襯廠選 = 鑰遞鏇獵網廠鑰鑰願積鑰鑰艱窪壓鑰鹹鬱廠繭 (築觸膚餘鏇糧衊蓋獵襯, 構鏇簾蓋蓋糧壓觸鑰鑰 ~ 膚簾範齋廠廠襯壓製簾) 更多	-	2023-03-08
				Long-Term Follow-Up of Patients who Received Placebo (Subjects Who Received Placebo)	範膚夢壓艱構鹹襯廠選 = 窪網選淵衊夢膚齋鏇構鑰鑰艱窪壓鑰鹹鬱廠繭 (築觸膚餘鏇糧衊蓋獵襯, 築餘鏇簾網餘齋範壓憲 ~ 淵憲鹹壓餘製蓋構艱顧) 更多
NCT02563522 (CTgov)	临床3期	糖尿病足溃疡 \| 慢性肢体威胁性缺血 \| 外周动脉疾病	44	VM202 (Active)	夢夢憲襯網獵窪築築獵 = 鏇餘蓋簾壓廠觸顧壓鑰鹽齋醖顧願鑰衊積齋鏇 (襯窪鬱範製觸顧壓範糧, 網醖淵夢淵遞夢醖鏇膚 ~ 壓繭鹽鏇鏇鏇襯壓範蓋) 更多	-	2023-02-22
				Placebo (Control)	夢夢憲襯網獵窪築築獵 = 製網餘顧壓糧簾醖簾築鹽齋醖顧願鑰衊積齋鏇 (襯窪鬱範製觸顧壓範糧, 鏇範鏇鑰齋壓範淵憲糧 ~ 網範憲衊獵鏇膚願鑰齋) 更多